Abstract
Acute myeloid leukemia with high ecotropic viral integration site-1 expression (EVI1high AML) is classified as a refractory type of leukemia with a poor prognosis. To provide new insights into the prevention and treatment of this disease, we identified the high expression of EVI1-regulated G protein-coupled receptor 56 (GPR56), and the association of high cell adhesion and antiapoptotic activities in EVI1high AML cells. Knockdown of GPR56 expression decreased the cellular adhesion ability through inactivation of RhoA signaling, resulting in a reduction of cellular growth rates and enhanced apoptosis. Moreover, in Gpr56−/− mice, the number of hematopoietic stem cells (HSCs) was significantly decreased in the bone marrow (BM) and, conversely, was increased in the spleen, liver and peripheral blood. The number of Gpr56−/− HSC progenitors in the G0/G1-phase was significantly reduced and was associated with impaired cellular adhesion. Finally, the loss of GPR56 function resulted in a reduction of the in vivo repopulating ability of the HSCs. In conclusion, GPR56 may represent an important GPCR for the maintenance of HSCs by acting as a co-ordinator of interactions with the BM osteosteal niche; furthermore, this receptor has the potential to become a novel molecular target in EVI1high leukemia.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Ishikawa F, Yoshida S, Saito Y, Hijikata A, Kitamura H, Tanaka S et al. Chemotherapy-resistant human AML stem cells home to and engraft within the bone-marrow endosteal region. Nat Biotechnol 2007; 25: 1315–1321.
Lane SW, Scadden DT, Gilliland DG . The leukemic stem cell niche: current concepts and therapeutic opportunities. Blood 2009; 114: 1150–1157.
Morishita K, Parker DS, Mucenski ML, Jenkins NA, Copeland NG, Ihle JN . Retroviral activation of a novel gene encoding a zinc finger protein in IL-3-dependent myeloid leukemia cell lines. Cell 1988; 54: 831–840.
Morishita K, Parganas E, William CL, Whittaker MH, Drabkin H, Oval J et al. Activation of EVI1 gene expression in human acute myelogenous leukemias by translocations spanning 300–400 kilobases on chromosome band 3q26. Proc Natl Acad Sci USA. 1992; 89: 3937–3941.
Lugthart S, Gröschel S, Beverloo HB, Kayser S, Valk PJ, van Zelderen-Bhola SL et al. Clinical, molecular, and prognostic significance of WHO type inv(3)(q21q26.2)/t(3;3)(q21;q26.2) and various other 3q abnormalities in acute myeloid leukemia. J Clin Oncol 2010; 28: 3890–3898.
Barjesteh van Waalwijk van Doorn-Khosrovani S, Erpelinck C, van Putten WL, Valk PJ, van der Poel-van de Luytgaarde S, Hack R et al. High EVI1 expression predicts poor survival in acute myeloid leukemia: a study of 319 de novo AML patients. Blood 2003; 101: 837–845.
Lugthart S, van Drunen E, van Norden Y, van Hoven A, Erpelinck CA, Valk PJ et al. High EVI1 levels predict adverse outcome in acute myeloid leukemia: prevalence of EVI1 overexpression and chromosome 3q26 abnormalities underestimated. Blood 2008; 111: 4329–4337.
Groschel S, Lugthart S, Schlenk RF, Valk PJ, Eiwen K, Goudswaard C et al. High EVI1 expression predicts outcome in younger adult patients with acute myeloid leukemia and is associated with distinct cytogenetic abnormalities. J Clin Oncol 2010; 28: 2101–2107.
Valk PJ, Verhaak RG, Beijen MA, Erpelinck CA, Barjesteh van Waalwijk van Doorn-Khosrovani S, Boer JM et al. Prognostically useful gene-expression profiles in acute myeloid leukemia. N Engl J Med 2004; 350: 1617–1628.
Verhaak RG, Wouters BJ, Erpelinck CA, Abbas S, Beverloo HB, Lugthart S et al. Prediction of molecular subtype in acute myeloid leukemia based on gene expression profiling. Haematologica 2009; 94: 131–134.
Eppert K, Takenaka K, Lechman ER, Waldron L, Nilsson B, van Galen P et al. Stem cell gene expression programs influence clinical outcome in human leukemia. Nat Med 2011; 17: 1086–1093.
Yuasa H, Oike Y, Iwama A, Nishikata I, Sugiyama D, Perkins A et al. Oncogenic transcription factor Evi1 regulates hematopoietic stem cell proliferation through GATA-2 expression. EMBO J. 2005; 24: 1976–1987.
Goyama S, Yamamoto G, Shimabe M, Sato T, Ichikawa M, Ogawa S et al. Evi-1 is a critical regulator for hematopoietic stem cells and transformed leukemic cells. Cell Stem Cell 2008; 3: 207–220.
Saito Y, Nakahata S, Yamakawa N, Kaneda K, Ichihara E, Suekane A et al. CD52 as a molecular target for immunotherapy to treat acute myeloid leukemia with high EVI1 expression. Leukemia 2011; 25: 921–931.
Yamakawa N, Kaneda K, Saito Y, Ichihara E, Morishita K . The increased expression of integrin a6 (ITGA6) enhances drug resistance in EVI1high leukemia. PLoS ONE 2012; 7: e30706.
Ichihara E, Kaneda K, Saito Y, Yamakawa N, Morishita K . Angiopoietin1 contributes to the maintenance of cell quiescence in EVI1high leukemia cells. BBRC 2011; 416: 239–245.
Piao X, Hill RS, Bodell A, Chang BS, Basel-Vanagaite L, Straussberg R et al. G protein-coupled receptor-dependent development of human frontal cortex. Science 2004; 303: 2033–2036.
Li S, Jin Z, Koirala S, Bu L, Xu L, Hynes RO et al. GPR56 regulates pial basement membrane integrity and cortical lamination. J Neurosci 2008; 28: 5817–5826.
Koirala S, Jin Z, Piao X, Corfas G . GPR56-regulated granule cell adhesion is essential for rostral cerebellar development. J Neurosci 2009; 29: 7439–7449.
Iguchi T, Sakata K, Yoshizaki K, Tago K, Mizuno N, Itoh H . Orphan G protein-coupled receptor GPR56 regulates neural progenitor cell migration via a G alpha 12/13 and Rho pathway. J Biol Chem 2008; 283: 14469–14478.
Shashidhar S, Lorente G, Nagavarapu U, Nelson A, Kuo J, Cummins J et al. GPR56 is a GPCR that is overexpressed in gliomas and functions in tumor cell adhesion. Oncogene 2005; 24: 1673–1682.
Xu L, Begum S, Hearn JD, Hynes RO . GPR56, an atypical G protein-coupled receptor, binds tissue transglutaminase, TG2, and inhibits melanoma tumor growth and metastasis. Proc Natl Acad Sci USA 2006; 103: 9023–9028.
Ke N, Sundaram R, Liu G, Chionis J, Fan W, Rogers C et al. Orphan G protein-coupled receptor GPR56 plays a role in cell transformation and tumorigenesis involving the cell adhesion pathway. Mol Cancer Ther 2007; 6: 1840–1850.
Terskikh AV, Easterday MC, Li L, Hood L, Kornblum HI, Geschwind DH et al. From hematopoiesis to neuropoiesis: evidence of overlapping genetic programs. Proc Natl Acad Sci USA 2001; 98: 7934–7939.
Yang FC, Atkinson SJ, Gu Y, Borneo JB, Roberts AW, Zheng Y et al. Rac and Cdc42 GTPases control hematopoietic stem cell shape, adhesion, migration, and mobilization. Proc Natl Acad Sci USA 2001; 98: 5614–5618.
Cancelas JA, Lee AW, Prabhakar R, Stringer KF, Zheng Y, Williams DA . Rac GTPases differentially integrate signals regulating hematopoietic stem cell localization. Nat Med 2005; 11: 886–891.
Gu Y, Filippi MD, Cancelas JA, Siefring JE, Williams EP, Jasti AC et al. Hematopoietic cell regulation by Rac1 and Rac2 guanosine triphosphatases. Science 2003; 302: 445–449.
Ghiaur G, Lee A, Bailey J, Cancelas JA, Zheng Y, Williams DA . Inhibition of RhoA GTPase activity enhances hematopoietic stem and progenitor cell proliferation and engraftment. Blood 2006; 108: 2087–2094.
Yang L, Wang L, Geiger H, Cancelas JA, Mo J, Zheng Y . Rho GTPase Cdc42 coordinates hematopoietic stem cell quiescence and niche interaction in the bone marrow. Proc Natl Acad Sci USA 2007; 104: 5091–5096.
Ghiaur G, Ferkowicz MJ, Milsom MD, Bailey J, Witte D, Cancelas JA et al. Rac1 is essential for intraembryonic hematopoiesis and for the initial seeding of fetal liver with definitive hematopoietic progenitor cells. Blood 2008; 111: 3313–3321.
Luo R, Jeong SJ, Jin Z, Strokes N, Li S, Piao X . G protein-coupled receptor 56 and collagen III, a receptor-ligand pair, regulates cortical development and lamination. Proc Natl Acad Sci USA 2011; 108: 12925–12930.
Xu H, Eleswarapu S, Geiger H, Szczur K, Daria D, Zheng Y et al. Loss of Rho GTPase activating protein p190-B enhances hematopoietic stem cell engraftment potential. Blood 2009; 114: 3557–3566.
Acknowledgements
We gratefully acknowledge Genentech for providing the Gpr56 knockout mice for the studies. This work was supported by a grant-in-aid for the third term comprehensive 10-year strategy for cancer control from the Ministry of Health and Welfare; a grant-in-aid for scientific research from The Ministry of Education, Culture, Sports, Science and Technology; a grant-in-aid for scientific research from the Japan Society for the Promotion of Science; and a Grant-in-Aid for Scientific Research on Innovative Areas.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Additional information
Supplementary Information accompanies this paper on the Leukemia website
Supplementary information
Rights and permissions
About this article
Cite this article
Saito, Y., Kaneda, K., Suekane, A. et al. Maintenance of the hematopoietic stem cell pool in bone marrow niches by EVI1-regulated GPR56. Leukemia 27, 1637–1649 (2013). https://doi.org/10.1038/leu.2013.75
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/leu.2013.75
Keywords
This article is cited by
-
Signaling pathways in cancer metabolism: mechanisms and therapeutic targets
Signal Transduction and Targeted Therapy (2023)
-
CGRP-CRLR/RAMP1 signal is important for stress-induced hematopoiesis
Scientific Reports (2019)
-
Suppression of GPR56 expression by pyrrole-imidazole polyamide represents a novel therapeutic drug for AML with high EVI1 expression
Scientific Reports (2018)
-
Restricted cell cycle is essential for clonal evolution and therapeutic resistance of pre-leukemic stem cells
Nature Communications (2018)
-
GPCRs profiling and identification of GPR110 as a potential new target in HER2+ breast cancer
Breast Cancer Research and Treatment (2018)